We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Bayer AG | TG:BAYN | Tradegate | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.47 | 1.64% | 29.165 | 29.125 | 29.20 | 29.40 | 28.68 | 28.945 | 207,523 | 22:50:04 |
From Sep 2019 to Sep 2024
By Kim Richters
Germany's Bayer AG (BAYN.XE) said Wednesday that it has led a financing round in a U.S. startup researching potential cancer treatments.
The German conglomerate, which is battling legal cases in the U.S. tying its Roundup weedkiller to cancer, said it had invested $11 million in startup Pyxis Oncology via its investment arm Leaps by Bayer. Investors Agent Capital, Ipsen and Longwood Fund also contributed another $11 million, according to Bayer.
The newly founded Pyxis aims to develop antibody-based immunotherapies for cancer patients.
Write to Kim Richters at kim.richters@wsj.com
(END) Dow Jones Newswires
July 17, 2019 09:25 ET (13:25 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Bayer Chart |
1 Month Bayer Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
